HC Wainwright Issues Pessimistic Outlook for XENE Earnings

Key Points

• HC Wainwright has reduced its Q3 2025 earnings estimates for Xenon Pharmaceuticals to ($1.26) per share, down from ($1.25), while maintaining a "Buy" rating with a target price of $53.00.
• Xenon Pharmaceuticals reported a quarterly loss of ($1.07) EPS, missing analysts' expectations by ($0.04), and has seen recent downgrades from some research firms.
• The stock is currently priced at $37.67, showing a 4.7% increase recently, with institutional investors owning approximately 95.45% of the company's shares.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Stock analysts at HC Wainwright reduced their Q3 2025 EPS estimates for Xenon Pharmaceuticals in a research report issued on Tuesday, August 12th. HC Wainwright analyst D. Tsao now forecasts that the biopharmaceutical company will post earnings per share of ($1.26) for the quarter, down from their previous forecast of ($1.25). HC Wainwright currently has a "Buy" rating and a $53.00 target price on the stock. The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.10) per share. HC Wainwright also issued estimates for Xenon Pharmaceuticals' Q4 2025 earnings at ($1.33) EPS, FY2025 earnings at ($4.49) EPS, Q1 2026 earnings at ($1.33) EPS, Q3 2026 earnings at ($1.31) EPS, Q4 2026 earnings at ($1.43) EPS, FY2026 earnings at ($5.40) EPS, FY2027 earnings at ($5.98) EPS, FY2028 earnings at ($5.28) EPS and FY2029 earnings at ($3.79) EPS.

Several other brokerages also recently commented on XENE. Wall Street Zen downgraded shares of Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. William Blair reiterated an "outperform" rating on shares of Xenon Pharmaceuticals in a report on Monday, May 5th. Wedbush lifted their target price on shares of Xenon Pharmaceuticals from $42.00 to $43.00 and gave the stock an "outperform" rating in a report on Tuesday, August 12th. Chardan Capital restated a "buy" rating and set a $55.00 price objective on shares of Xenon Pharmaceuticals in a report on Tuesday, August 12th. Finally, Evercore ISI initiated coverage on shares of Xenon Pharmaceuticals in a report on Wednesday, May 14th. They set an "outperform" rating and a $55.00 price objective on the stock. One research analyst has rated the stock with a sell rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $53.20.

Xenon Pharmaceuticals Stock Performance

Shares of Xenon Pharmaceuticals stock traded up $0.27 during midday trading on Thursday, reaching $38.23. 820,100 shares of the company's stock traded hands, compared to its average volume of 1,051,328. The company has a market cap of $2.95 billion, a price-to-earnings ratio of -10.77 and a beta of 1.16. The company's 50 day simple moving average is $32.59 and its 200 day simple moving average is $34.02. Xenon Pharmaceuticals has a 52 week low of $26.74 and a 52 week high of $46.00.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its earnings results on Monday, August 11th. The biopharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.03) by ($0.04). During the same quarter in the prior year, the business earned ($0.75) EPS.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of hedge funds have recently made changes to their positions in XENE. Farther Finance Advisors LLC acquired a new stake in Xenon Pharmaceuticals during the 2nd quarter worth approximately $25,000. Caitong International Asset Management Co. Ltd acquired a new stake in Xenon Pharmaceuticals during the 1st quarter worth approximately $30,000. Elevation Point Wealth Partners LLC bought a new position in Xenon Pharmaceuticals during the 2nd quarter worth approximately $32,000. GF Fund Management CO. LTD. bought a new position in Xenon Pharmaceuticals during the 4th quarter worth approximately $63,000. Finally, Quarry LP bought a new position in Xenon Pharmaceuticals during the 4th quarter worth approximately $78,000. 95.45% of the stock is currently owned by institutional investors and hedge funds.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.